*Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") and Hong Kong Securities Clearing Company Limited ("**HKSCC**") take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 22, 2026 (the "**Prospectus**") of Jiangxi Institute of Biological Products Inc. (江西生物製品研究所股份有限公司) (the "**Company**").*

This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for any securities. This announcement is not a prospectus. Potential investors should read the Prospectus for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares. Any investment decision in relation to the Offer Shares should be taken solely in reliance on the information provided in the Prospectus.

*This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia). This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States or in any other jurisdictions. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act of 1933 as amended from time to time (the "**U.S. Securities Act**") or securities law of any state or other jurisdiction of the United States. The securities may not be offered, sold, pledged or otherwise transferred within the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws, or outside the United States unless in compliance with Regulation S under the U.S. Securities Act. There will be no public offer of securities in the United States.*

*In connection with the Global Offering, China International Capital Corporation Hong Kong Securities Limited as stabilizing manager (the "**Stabilizing Manager**") (or its affiliates or any person acting for it), on behalf of the Underwriters, to the extent permitted by the applicable laws and regulatory requirements of Hong Kong or elsewhere, may over-allocate or effect transactions with a view to stabilizing or supporting the market price of the H Shares at such price, in such amounts and in such manners as the Stabilizing Manager, its affiliates or any person acting for it may determine and at a level higher than that which might otherwise prevail for a limited period after the Listing Date. However, there is no obligation on the Stabilizing Manager (or its affiliates or any person acting for it) to conduct any such stabilizing action. Such stabilizing action, if taken, (a) will be conducted at the absolute discretion of the Stabilizing Manager (or its affiliates or any person acting for it) and in what the Stabilizing Manager reasonably regards as the best interest of the Company, (b) may be discontinued at any time and (c) is required to be brought to an end within 30 days of the last day for lodging applications under the Hong Kong Public Offering (which is Saturday, July 25, 2026). Such stabilizing action, if taken, may be effected in all jurisdictions where it is permissible to do so, in each case in compliance with all applicable laws, rules and regulatory requirements, including the Securities and Futures (Price Stabilizing) Rules (Chapter 571W of the Laws of Hong Kong), as amended, made under the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).*

Potential investors should be aware that no stabilizing action can be taken to support the price of the H Shares for longer than the stabilization period, which will begin on the Listing Date, and is expected to expire on the 30th day after the last day for lodging applications under the Hong Kong Public Offering (which is Saturday, July 25, 2026). After this date, when no further stabilizing action may be taken, demand for the H Shares, and therefore the price of the H Shares, could fall.

The Hong Kong Offer Shares will be offered to the public in Hong Kong subject to the terms and conditions set out in the Prospectus. The Hong Kong Offer Shares will not be offered to any person who is outside Hong Kong and/or not resident in Hong Kong. Potential investors of the Offer Shares should note that the Joint Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate the Hong Kong Underwriting Agreement with immediate effect upon the occurrence of any of the events set out in the section headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. on the Listing Date.

Jiangxi Institute of Biological Products Inc.
江 西 生 物 製 品 研 究 所 股 份 有 限 公 司

(A joint stock company incorporated in the People's Republic of China with limited liability)

Global Offering

Number of Offer Shares under the Global Offering	:	36,234,500 H Shares (subject to the Over-allotment Option)
Number of Hong Kong Offer Shares	:	3,623,500 H Shares
Number of International Offer Shares	:	32,611,000 H Shares (subject to the Over-allotment Option)
Final Offer Price	:	HK$11.20 per H Share, plus brokerage of 1.0%, SFC transaction levy of 0.0027%, AFRC transaction levy of 0.00015% and the Stock Exchange trading fee of 0.00565% (payable in full on application in Hong Kong Dollars, subject to refund)
Nominal value	:	RMB1.00 per H Share
Stock code	:	6915

Joint Sponsors, Sponsor-Overall Coordinators, Joint Overall Coordinators, Joint Global Coordinators, Joint Bookrunners and Joint Lead Managers

Joint Overall Coordinator, Joint Global Coordinator, Joint Bookrunner and Joint Lead Manager

Joint Bookrunners and Joint Lead Managers

Jiangxi Institute of Biological Products Inc.
江西生物製品研究所股份有限公司

ANNOUNCEMENT OF ALLOTMENT RESULTS

*Unless otherwise defined herein, capitalized terms used in this announcement shall have the same meanings as those defined in the prospectus dated June 22, 2026 (the "**Prospectus**") issued by Jiangxi Institute of Biological Products Inc. (江西生物製品研究所股份有限公司) (the "**Company**").*

Warning: In view of high concentration of shareholding in a small number of H Shareholders, Shareholders and prospective investors should be aware that the price of the H Shares could move substantially even with a small number of H Shares traded and should exercise extreme caution when dealing in the H Shares.

SUMMARY

Company information	
Stock Code	6915
Stock Short Name	JIANGXI BIO
Dealings commencement date	June 30, 2026*

* *see note at the end of the announcement*

Price Information	
Final Offer Price	HK$11.20

Offer Shares and Share Capital	
Number of Offer Shares (before exercise of the Over-allotment Option)	36,234,500 H Shares
Final Number of Offer Shares in Hong Kong Public Offering	3,623,500 H Shares
Final Number of Offer Shares in International Offering (before exercise of the Over-allotment Option)	32,611,000 H Shares
Number of issued Shares upon Listing (before exercise of the Over-allotment Option)	308,377,319

Over-allocation	
No. of Offer Shares over-allocated	5,435,000 H Shares
Such over-allocated Offer Shares may be covered by exercising the Over-allotment Option or by making purchases in the secondary market at prices that do not exceed the Offer Price or by a combination of these means. In the event the Over-allotment Option is exercised, an announcement will be made on the Stock Exchange's website.	

Proceeds	
Gross proceeds (Note)	HK$405.83 million
Less: Estimated listing expenses payable based on Final Offer Price	HK$67.03 million
Net proceeds	HK$338.80 million

Note: Gross proceeds refer to the amount which the Company is entitled to receive. For details of the use of proceeds, please refer to the section headed "Future Plans and Use of Proceeds" of the Prospectus. The Company will adjust the allocation of the net proceeds from the exercise of the Over-allotment Option (if any) for the purposes as set out in the section headed "Future Plans and Use of Proceeds" of the Prospectus on a pro rata basis.

ALLOTMENT RESULTS DETAILS

HONG KONG PUBLIC OFFERING

No. of valid applications	78,433
No. of successful applications	5,152
Subscription level	476.56 times
Claw-back triggered	N/A
No. of Offer Shares initially available under the Hong Kong Public Offering	3,623,500 H Shares
No. of Offer Shares reallocated from the International Offering	0 H Shares
Final no. of Offer Shares under the Hong Kong Public Offering	3,623,500 H Shares
% of Offer Shares under the Hong Kong Public Offering to the Global Offering (before exercise of the Over-allotment Option)	10%

Note: For details of the final allocation of H Shares to the Hong Kong Public Offering, investors can refer to https://www.hkeipo.hk/iporesult to perform a search by identification document number or https://www.hkeipo.hk/iporesult for the full list of allottees.

INTERNATIONAL OFFERING

No. of placees	63
Subscription Level	4.25 times
No. of Offer Shares initially available under the International Offering	32,611,000 H Shares
No. of Offer Shares reallocated to the Hong Kong Public Offering	0 H Shares
Final no. of Offer Shares under the International Offering (before exercise of the Over-allotment Option)	32,611,000 H Shares
% of Offer Shares under the International Offering to the Global Offering (before exercise of the Over-allotment Option)	90%

The Directors confirm that, to the best of their knowledge, information and belief, (i) none of the Offer Shares subscribed by the placees and the public have been financed directly or indirectly by the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates; and (ii) none of the placees and the public who have purchased the Offer Shares are accustomed to taking instructions from the Company, any of the Directors, chief executive of the Company, Controlling Shareholders, substantial Shareholders, existing Shareholders of the Company or any of its subsidiaries or their respective close associates in relation to the acquisition, disposal, voting or other disposition of H Shares registered in his/her/its name or otherwise held by him/her/it.

The placees in the International Offering include the following:

Cornerstone Investor

Investor[Note 1]	*No. of Offer Shares allocated*	*% of Offer Shares (assuming the Over-allotment Option is not exercised)*	*% of total issued share capital in the Company after the Global Offering (assuming the Over-allotment Option is not exercised)*	*Existing shareholders or their close associates*
Wealth Strategy Holding Limited	4,464,000	12.32%	1.45%	No
Total	**4,464,000**	**12.32%**	**1.45%**	

Note:

1. *For further details of the Cornerstone Investor, please refer to the section headed "Cornerstone Investor" in the Prospectus.*

LOCK-UP UNDERTAKINGS

Controlling Shareholders

Name	*Number of Shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 1]
Shenzhen Qianhai Tianzheng Biotechnology Co., Ltd.	203,687,250 H Shares	66.05%	June 29, 2027
Hainan Zhizheng Biotechnology Development Co., Ltd.	4,875,000 H Shares	1.58%	June 29, 2027
Total	**208,562,250**	**67.63%**	

Notes:

1. *The expiry date of the lock-up period shown in the table above is pursuant to the PRC Company Law. The required lock-up for the Controlling Shareholders ends on June 29, 2027, being the date twelve months following the Listing Date. For illustrative purposes only, this subsection lists only those members of the Controlling Shareholders who hold Shares directly in the Company. Pursuant to Rule 10.07 of the Listing Rules, each Controlling Shareholder (namely, Ms. Jing Yue, Shenzhen Qianhai Tianzheng Biotechnology Co., Ltd. and Hainan Zhizheng Biotechnology Development Co., Ltd.) has undertaken to the Stock Exchange and the Company that she or it shall comply with the applicable lock-up requirements. For further details, please refer to the section headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Undertakings to the Stock Exchange Pursuant to the Listing Rules — Undertakings by the Controlling Shareholders" in the Prospectus.*

2. *Upon completion of the Global Offering, 270,855,819 Domestic Shares will be converted into H Shares on a one-for-one basis.*

Cornerstone Investor

Name	*Number of Shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 1]
Wealth Strategy Holding Limited	4,464,000 H Shares	1.45%	December 29, 2026
Total	**4,464,000**	**1.45%**	

Note:

1. *In accordance with the relevant cornerstone investment agreement, the required lock-up ends on December 29, 2026. The Cornerstone Investor will cease to be prohibited from disposing of or transferring H Shares subscribed pursuant to the relevant cornerstone investment agreement after the indicated date.*

Pre-IPO Investors

Name	*Number of Shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 1]
Chifeng Bo-en Jingtian Technology Co., Ltd.	5,070,000 H Shares	1.64%	June 29, 2027
Chongqing Hanyi Cultural Exchange Co., Ltd.	12,675,000 H Shares	4.11%	June 29, 2027
Shenzhen Xiangyi Investment Guarantee Co., Ltd.	6,337,500 H Shares	2.06%	June 29, 2027
YANG Kun	3,315,000 H Shares	1.07%	June 29, 2027
Hainan Ruiqingxiang Investment Partnership (Limited Partnership)	2,125,090 H Shares	0.69%	June 29, 2027

Name	*Number of Shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 1]
Jiaxing Jiaci Erhuijing Equity Investment Partnership (Limited Partnership)	1,287,000 Domestic Shares	0.42%	June 29, 2027
LIN Lin	975,000 H Shares	0.32%	June 29, 2027
XU Qinhong	780,000 H Shares	0.25%	June 29, 2027
OUYANG Guishou	585,000 H Shares	0.19%	June 29, 2027
RONG Zhiyao	585,000 H Shares	0.19%	June 29, 2027
WANG Pengjie	585,000 H Shares	0.19%	June 29, 2027
Chongqing Hanxin Pharmaceutical Co., Ltd.	507,000 H Shares	0.16%	June 29, 2027
Jiangsu Hailei Pharmaceutical Co., Ltd.	507,000 H Shares	0.16%	June 29, 2027
Shenzhen Heli No. 7 Investment Center (Limited Partnership)	507,000 H Shares	0.16%	June 29, 2027
ZHANG Yiyu	468,000 H Shares	0.15%	June 29, 2027
WEN Yejuan	429,000 H Shares	0.14%	June 29, 2027
CHEN Guangai	390,000 H Shares	0.13%	June 29, 2027
LU Changying	390,000 H Shares	0.13%	June 29, 2027
ZHANG Zhide	390,000 H Shares	0.13%	June 29, 2027
MA Ying	292,500 H Shares	0.09%	June 29, 2027
LI Yulun	195,000 H Shares	0.06%	June 29, 2027
ZHANG Ruoshi	195,000 H Shares	0.06%	June 29, 2027
LONG Yehong	195,000 H Shares	0.06%	June 29, 2027
DAI Yujian	195,000 H Shares	0.06%	June 29, 2027
Shenzhen Lingyao Investment Partnership (Limited Partnership)	136,500 H Shares	0.04%	June 29, 2027
ZHU Luwen	117,000 H Shares	0.04%	June 29, 2027
LUO Qian	117,000 H Shares	0.04%	June 29, 2027

Name	*Number of Shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings*[Note 1]
LI Xiaoying	97,500 H Shares	0.03%	June 29, 2027
LU Ruiheng	97,500 H Shares	0.03%	June 29, 2027
SONG Hongxia	97,500 H Shares	0.03%	June 29, 2027
WEN Anhua	97,500 H Shares	0.03%	June 29, 2027
WU Hao	97,500 H Shares	0.03%	June 29, 2027
WU Hong	97,500 H Shares	0.03%	June 29, 2027
WU Jianying	97,500 H Shares	0.03%	June 29, 2027
ZHU Guiju	97,500 H Shares	0.03%	June 29, 2027
XU Quanhua	39,000 H Shares	0.01%	June 29, 2027
GUO Lihong	39,000 H Shares	0.01%	June 29, 2027
HE Qunhua	39,000 H Shares	0.01%	June 29, 2027
WANG Weiling	29,250 H Shares	0.01%	June 29, 2027
YU Xiaoyan	19,500 H Shares	0.01%	June 29, 2027
Total	**40,296,340**	**13.07%**	

Notes:

1. *Under the applicable PRC laws, all existing Shareholders are subject to a lock-up period of twelve months following the Listing Date.*

2. *Upon completion of the Global Offering, 270,855,819 Domestic Shares will be converted into H Shares on a one-for-one basis.*

Other Existing Shareholders

Name	*Number of Shares held in the Company subject to lock-up undertakings upon Listing*	*% of total issued share capital in the Company subject to lock-up undertakings upon Listing (assuming the Over-allotment Option is not exercised)*	*Last day subject to the lock-up undertakings[Note 1]*
Hainan Huafengming Investment Partnership (Limited Partnership)	3,597,419 H Shares	1.17%	June 29, 2027
ZENG Hong	760,500 H Shares	0.25%	June 29, 2027
Hainan Gangyuanhao Investment Partnership (Limited Partnership)	674,310 H Shares	0.22%	June 29, 2027
Ji'an Aohai Industrial Development Co., Ltd.	12,675,000 H Shares	4.11%	June 29, 2027
Haikou Tianshun Industrial Development Co., Ltd.	4,563,000 H Shares	1.48%	June 29, 2027
LIU Yurui	1,014,000 H Shares	0.33%	June 29, 2027
Total	**23,284,229**	**7.55%**	

Notes:

1. *Under the applicable PRC laws, all existing Shareholders are subject to a lock-up period of twelve months following the Listing Date.*

2. *Upon completion of the Global Offering, 270,855,819 Domestic Shares will be converted into H Shares on a one-for-one basis.*

PLACEE CONCENTRATION ANALYSIS

Placees*	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over- allotment Option is fully exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of H Shares held upon Listing	% of total H Shares upon Listing (assuming no exercise of the Over- allotment Option)	% of total H Shares upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)
Top 1	4,464,000	13.69%	11.73%	12.32%	10.71%	4,464,000	1.45%	1.43%	1.45%	1.42%
Top 5	16,814,500	51.56%	44.20%	46.40%	40.35%	16,814,500	5.48%	5.38%	5.45%	5.36%
Top 10	22,906,500	70.24%	60.21%	63.22%	54.97%	22,906,500	7.46%	7.33%	7.43%	7.30%
Top 25	32,869,000	100.79%	86.39%	90.71%	78.88%	32,869,000	10.70%	10.52%	10.66%	10.47%

Note:

* *Ranking of placees is based on the number of H Shares allotted to the placees.*

H SHAREHOLDER CONCENTRATION ANALYSIS

H Shareholders*	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over- allotment Option is fully exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over- allotment Option)	Allotment as % of total Offer Shares (assuming the Over- allotment Option is fully exercised and new H Shares are issued)	Number of H Shares held upon Listing	% of total issued H share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued H share capital upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of Shares held upon Listing
Top 1	0	0.00%	0.00%	0.00%	0.00%	208,562,250	67.92%	66.73%	67.63%	66.46%	208,562,250
Top 5	0	0.00%	0.00%	0.00%	0.00%	245,319,750	79.89%	78.50%	79.55%	78.17%	245,319,750
Top 10	11,979,000	36.73%	31.49%	33.06%	28.75%	266,219,669	86.69%	85.18%	86.33%	84.83%	266,219,669
Top 25	26,467,500	81.16%	69.57%	73.05%	63.52%	288,176,259	93.84%	92.21%	93.45%	91.83%	288,176,259

Note:

* *Ranking of H Shareholders is based on the number of H Shares held by the H Shareholders upon Listing.*

SHAREHOLDER CONCENTRATION ANALYSIS

Shareholders*	Number of H Shares allotted	Allotment as % of International Offering (assuming no exercise of the Over-allotment Option)	Allotment as % of International Offering (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Allotment as % of total Offer Shares (assuming no exercise of the Over-allotment Option)	Allotment as % of total Offer Shares (assuming the Over-allotment Option is fully exercised and new H Shares are issued)	Number of H Shares held upon Listing	Number of Shares held upon Listing	% of total issued share capital upon Listing (assuming no exercise of the Over-allotment Option)	% of total issued share capital upon Listing (assuming the Over-allotment Option is fully exercised and new H Shares are issued)
Top 1	0	0.00%	0.00%	0.00%	0.00%	208,562,250	208,562,250	67.63%	66.46%
Top 5	0	0.00%	0.00%	0.00%	0.00%	245,319,750	245,319,750	79.55%	78.17%
Top 10	11,979,000	36.73%	31.49%	33.06%	28.75%	266,219,669	266,219,669	86.33%	84.83%
Top 25	25,584,000	78.45%	67.24%	70.61%	61.40%	287,292,759	288,579,759	93.58%	91.96%

Note:

* *Ranking of Shareholders is based on the number of Shares (of all classes) held by the Shareholders upon Listing.*

BASIS OF ALLOCATION UNDER THE HONG KONG PUBLIC OFFERING

Subject to the satisfaction of the conditions set out in the Prospectus, a total of 78,433 valid applications made by the public will be conditionally allocated on the basis set out below:

Pool A

Number of H Shares applied for	**Number of valid applications**	**Basis of allocations/ballot**	**Approximate percentage allotted of the total number of H Shares applied for**
500	51,007	1,021 out of 51,007 applicants to receive 500 H Shares	2.00%
1,000	4,827	138 out of 4,827 applicants to receive 500 H Shares	1.43%
1,500	1,490	53 out of 1,490 applicants to receive 500 H Shares	1.19%
2,000	1,140	47 out of 1,140 applicants to receive 500 H Shares	1.03%
2,500	1,011	47 out of 1,011 applicants to receive 500 H Shares	0.93%
3,000	607	31 out of 607 applicants to receive 500 H Shares	0.85%
3,500	3,343	182 out of 3,343 applicants to receive 500 H Shares	0.78%
4,000	553	33 out of 553 applicants to receive 500 H Shares	0.75%
4,500	268	17 out of 268 applicants to receive 500 H Shares	0.70%
5,000	3,122	204 out of 3,122 applicants to receive 500 H Shares	0.65%
6,000	554	40 out of 554 applicants to receive 500 H Shares	0.60%
7,000	831	65 out of 831 applicants to receive 500 H Shares	0.56%
8,000	470	39 out of 470 applicants to receive 500 H Shares	0.52%
9,000	284	25 out of 284 applicants to receive 500 H Shares	0.49%
10,000	1,064	99 out of 1,064 applicants to receive 500 H Shares	0.47%
15,000	594	68 out of 594 applicants to receive 500 H Shares	0.38%
20,000	429	57 out of 429 applicants to receive 500 H Shares	0.33%
25,000	432	65 out of 432 applicants to receive 500 H Shares	0.30%
30,000	369	61 out of 369 applicants to receive 500 H Shares	0.28%
35,000	262	47 out of 262 applicants to receive 500 H Shares	0.26%
40,000	298	57 out of 298 applicants to receive 500 H Shares	0.24%
45,000	249	51 out of 249 applicants to receive 500 H Shares	0.23%
50,000	594	126 out of 594 applicants to receive 500 H Shares	0.21%
60,000	267	63 out of 267 applicants to receive 500 H Shares	0.20%
70,000	203	52 out of 203 applicants to receive 500 H Shares	0.18%
80,000	292	79 out of 292 applicants to receive 500 H Shares	0.17%
90,000	178	51 out of 178 applicants to receive 500 H Shares	0.16%
100,000	1,315	398 out of 1,315 applicants to receive 500 H Shares	0.15%
200,000	449	194 out of 449 applicants to receive 500 H Shares	0.11%
300,000	403	214 out of 403 applicants to receive 500 H Shares	0.09%
Total	**76,905**	**Total number of Pool A successful applicants: 3,624**	

Pool B

Number of H Shares applied for	Number of valid applications	Basis of allocations/ballot	Approximate percentage allotted of the total number of H Shares applied for
400,000	707	1,000 H Shares	0.25%
500,000	192	1,000 H Shares plus 34 out of 192 applicants to receive an additional 500 H Shares	0.22%
600,000	99	1,000 H Shares plus 30 out of 99 applicants to receive an additional 500 H Shares	0.19%
700,000	38	1,000 H Shares plus 17 out of 38 applicants to receive an additional 500 H Shares	0.17%
800,000	70	1,000 H Shares plus 38 out of 70 applicants to receive an additional 500 H Shares	0.16%
900,000	53	1,000 H Shares plus 35 out of 53 applicants to receive an additional 500 H Shares	0.15%
1,000,000	78	1,000 H Shares plus 58 out of 78 applicants to receive an additional 500 H Shares	0.14%
1,200,000	56	1,000 H Shares plus 52 out of 56 applicants to receive an additional 500 H Shares	0.12%
1,400,000	37	1,500 H Shares	0.11%
1,600,000	31	1,500 H Shares plus 7 out of 31 applicants to receive an additional 500 H Shares	0.10%
1,811,500	167	1,500 H Shares plus 61 out of 167 applicants to receive an additional 500 H Shares	0.09%
Total	**1,528**	**Total number of Pool B successful applicants: 1,528**	

As of the date of this announcement, the relevant subscription monies previously deposited in the designated nominee accounts have been remitted back to the accounts of all HKSCC participants. Investors should contact their relevant brokers for any inquiries.

COMPLIANCE WITH LISTING RULES AND GUIDANCE

The Directors confirm that, the Company has complied with the Listing Rules and guidance materials in relation to the placing, allotment and listing of the Company's H Shares.

The Directors confirm that, to the best of their knowledge, the consideration paid by the placees or the public (as the case may be) directly or indirectly for each Offer Share subscribed for or purchased by them was the same as the final Offer Price in addition to any brokerage, AFRC transaction levy, SFC transaction levy and Stock Exchange trading fee payable.

DISCLAIMERS

Hong Kong Exchanges and Clearing Limited, The Stock Exchange of Hong Kong Limited and Hong Kong Securities Clearing Company Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.
This announcement is not for release, publication, distribution, directly or indirectly, in or into the United States (including its territories and possessions, any state of the United States and the District of Columbia) or any other jurisdiction where such distribution is prohibited by law. This announcement does not constitute or form a part of any offer to sell or solicitation of an offer to buy, to purchase or subscribe for securities nor shall there be any sale of Offer Shares in the United States or in any other jurisdictions in which such offer or solicitation would be unlawful. The securities mentioned herein have not been, and will not be, registered under the United States Securities Act or any state securities law of the United States. The securities may not be offered, sold, pledged, or transferred within the United States or to, or for the account or benefit of U.S. persons (as defined in Regulation S) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the U.S. Securities Act and in compliance with any applicable state securities laws.
This announcement is for information purposes only and does not constitute an invitation or offer to acquire, purchase or subscribe for securities of the Company. This announcement is not a prospectus. Potential investors should read the Prospectus dated June 22, 2026 issued by Jiangxi Institute of Biological Products Inc. (江西生物製品研究所股份有限公司) for detailed information about the Global Offering described below before deciding whether or not to invest in the Offer Shares.
** Potential investors of the Offer Shares should note that the Joint Overall Coordinators (for themselves and on behalf of the Hong Kong Underwriters) shall be entitled to terminate their obligations under the Hong Kong Underwriting Agreement upon the occurrence of any of the events set out in the paragraph headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination" in the Prospectus at any time prior to 8:00 a.m. (Hong Kong time) on the Listing Date (which is currently expected to be Tuesday, June 30, 2026).*

PUBLIC FLOAT AND FREE FLOAT

Rule 19A.13A of the Listing Rules requires that where the expected market value of the Shares at the time of Listing is less than HK$6,000,000,000, at least 25% of the total number of the Shares must at the time of the Listing be held by the public.

Immediately after the completion of the Global Offering (before any exercise of the Over-allotment Option), an aggregate of 88,425,840 H Shares, representing approximately 28.67% of the total issued share capital of the Company will be counted towards the public float. Therefore, the Company will be able to meet the public float requirement under Rule 19A.13A(1) of the Listing Rules.

Rule 19A.13C(1) of the Listing Rules provides that, where a new applicant is a PRC issuer with no other listed shares at the time of listing, the portion of H shares for which listing is sought that are held by the public and not subject to any disposal restrictions at the time of listing must normally (i) represent at least 10% of the total number of issued shares in the class to which H shares belong at the time of listing (excluding treasury shares), with an expected market value at the time of listing of not less than HK$50,000,000; or (ii) have an expected market value at the time of listing of not less than HK$600,000,000.

Immediately after the completion of the Global Offering (before any exercise of the Over-allotment Option), based on the Offer Price of HK$11.20, except for (i) 272,142,819 Shares held by all existing Shareholders that are subject to a lock-up period of twelve months following the Listing Date under applicable PRC law; and (ii) 4,464,000 Shares held by Cornerstone Investor that are subject to a lock-up period of six months from and including the Listing Date, all remaining 31,770,500 Shares, representing approximately 10.30% of the total Shares, will be counted toward the free float. Therefore, the Company will be able to satisfy the free float requirement under Rule 19A.13C(1)(a) of the Listing Rules.

COMMENCEMENT OF DEALINGS

The H Share certificates will only become valid evidence of title at 8:00 a.m. on Tuesday, June 30, 2026 (Hong Kong time), provided that the Global Offering has become unconditional and the right of termination described in the section headed "Underwriting — Underwriting Arrangements and Expenses — Hong Kong Public Offering — Grounds for Termination" in the Prospectus has not been exercised. Investors who trade the H Shares on the basis of publicly available allocation details prior to the receipt of H Share certificates or prior to the H Share certificates becoming valid evidence of title do so entirely at their own risk.

Assuming that the Global Offering becomes unconditional at or before 8:00 a.m. on Tuesday, June 30, 2026 (Hong Kong time), it is expected that dealings in the H Shares on the Stock Exchange will commence at 9:00 a.m. on Tuesday, June 30, 2026 (Hong Kong time). The H Shares will be traded in board lots of 500 H Shares each, and the stock code of the H Shares will be 6915.

By order of the Board
Jiangxi Institute of Biological Products Inc.
Ms. JING Yue
Chairperson of the Board

Hong Kong, June 29, 2026

As of the date of this announcement, the Board of Directors of the Company comprises: (i) Ms. JING Yue, Mr. YAO Xiaodong, Mr. LI Changqing and Ms. JING Ruihua as executive Directors; (ii) Ms. YU Ailian and Mr. XIAO Changqing as non-executive Directors; and (iii) Dr. ZOU Pingxue, Dr. TSANG Hiu Leong and Mr. WU Di as independent non-executive Directors.